AzTrials
AzTrials

BronchiolitisNCT06376487

Pulmonary Aeration and Muscle Thickening Fraction: Association of Electrical Impedance Tomography and Ultrasound

A study testing Flow rate evaluation in people with Bronchiolitis, run by Hospital Israelita Albert Einstein at 1 site in Brazil.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this prospective clinical study is to evaluate the effect of different High Flow Nasal Cannula (HFNC) flow rates on diaphragm, rectoabdominal, and oblique thickening fraction, and to determine whether this effect depends on the action of HFNC flow rates on Functional Residual Capacity (FRC) in Infants… Read more about this study

Who is it for?
Ages Up to 24 months
Conditions the study is for
Bronchiolitis
What is being tested?
Flow rate evaluation
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
82 participants
Where
1 siteBrazil
Study dates
1 May 2024to 31 Jan 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 24 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Diagnosis of bronchiolitis
  • Use of HFNC

Who cannot join

  • Patients diagnosed with chronic diseases

Trial locations and contacts

1 site in 1 country.

Brazil1 site, 1 recruiting
  • Hospital Israelita Albert Eisntein

    São Paulo, 05653000

    Milena S Nascimento, 55 11 984520061, milena.nascimento@einstein.br

    Recruiting

Other trials in Brazil

About this study

Official title: Evaluation of Pulmonary Aeration and Muscle Thickening Fraction in Infants With Bronchiolitis Using a High-flow Nasal Cannula: Association of Electrical Impedance Tomography and Ultrasound

The goal of this prospective clinical study is to evaluate the effect of different High Flow Nasal Cannula (HFNC) flow rates on diaphragm, rectoabdominal, and oblique thickening fraction, and to determine whether this effect depends on the action of HFNC flow rates on Functional Residual Capacity (FRC) in Infants under 2 years of age with a diagnosis of bronchiolitis and indication for use of HFNC. The main question[s] it aims to answer are:

  • If the thickening fraction of the abdominal muscle and diaphragm will change at the different flow rates evaluated
  • If the end-expiration lung impedance (EELZ) will change at the different flow rates evaluated
Read more

The belt will be installed around the chest before the start of the change in flow rates and monitoring with Electrical Impedance Tomography (EIT) will be initiated. Patients will be positioned in dorsal decubitus elevated 10 to 20 degrees and monitoring will be performed continuously during all flow rate variations and also during the ultrasound performance.

Four different randomized flow rates will be used for evaluation: 2.0 liter.Kg-1.min-1, 1.5 liter.Kg-1.min-1, 1.0 liter.Kg-1.min-1, 0.5 liter.Kg-1.min-1. At the end of the randomized order evaluation the infant will remain in the flow of 0.5 liter.Kg-1.min-1 for 5 minutes and then return to the flow of 2.0 liter.Kg-1.min-1. The EIT parameters, ultrasound assessment, and clinical variables will be collected at the end of the 5-minute stay in each lane.

The randomization of the order of application of the phases will be carried out in blocks, so that the homogeneity of the sequences is maintained even if the collection is interrupted before reaching the total number of individuals. The blocks will be of size two and four and the test and production lists will be generated with the help of the R packages.

Read the detailed description

OBJECTIVES Main Objective To evaluate, in infants with respiratory failure secondary to bronchiolitis, the effect of different High Flow Nasal Cannula (HFNC) flow rates on diaphragm, rectoabdominal, and oblique thickening fraction, and to determine whether this effect depends on the action of HFNC flow rates on Functional Residual Capacity (FRC).

Secondary Objectives

  • To evaluate whether there is a correlation between thickening fraction and respiratory distress score.
  • To find values from the EIT data and the thickening fraction that can correlate with possible failure criteria for HFNC therapy.
  1. METHODS 5.1 Study Type and Location A prospective clinical study will be conducted in the Pediatric ICU of Hospital Israelite Albert Einstein from January 2024 to December 2025 5.2 Ethical Aspects This study will be submitted to the Ethics and Research Committee of the Hospital Israelite Albert Einstein. The risk of participating in this research is considered minimal, limited to the accidental loss of confidentiality of the data collected or to skin erythema at the site of application of the belt. Only after signing the informed consent form will the patient be prepared for the beginning of monitoring (Appendix 1) Protocol The tape will be installed around the chest before the start of the change in flow rates and monitoring with EIT will be initiated. Patients will be positioned in dorsal decubitus elevated 10 to 20 degrees and monitoring will be performed continuously during all flow rate variations and also during the ultrasound performance.

Four different randomized flow rates will be used for evaluation: 2.0 liter.Kg-1.min-1, 1.5 liter.Kg-1.min-1, 1.0 liter.Kg-1.min-1, 0.5 liter.Kg-1.min-1. At the end of the randomized order evaluation the infant will remain in the flow of 0.5 liter.Kg-1.min-1 for 5 minutes and then return to the flow of 2.0 liter.Kg-1.min-1. The EIT parameters, ultrasound assessment, and clinical variables will be collected at the end of the 5-minute stay in each lane.

5.5 Randomization: Randomization process The sequence of the flow values will be done using a tool software R 5.6 Clinical and demographic variables Demographic variables such as age, sex, Pediatric Index of Mortality Score (PIM2) (23) and viral screening will be collected when requested during routine hospitalization.

Of the clinical variables, respiratory rate (RR) will be assessed by counting the inspiratory cycles produced by EIT plethysmography in one minute. Heart rate (HR) and peripheral oxygen saturation (SpO2) will be obtained directly from the Infinity Delta multiparameter monitor (Dräger, Lubeck, Germany). Inspired oxygen fraction (FiO2). The Respiratory and Oxygenation Index (ROX index) will also be calculated, which is calculated by the ratio of SpO2/FiO2 by RR.

To evaluate respiratory distress, the investigators will use the respiratory distress score.

Electrical Impedance Tomography The recording of the electrical impedance variation over time is called plethysmogram and this provides information on the ventilation variation which is called Delta Z (∆Z) and has an excellent correlation with the volume variation assessed by computed tomography (25) and the minimum impedance (ZMIN) or ∆EELZ (end-expiration lung impedance) which is the baseline of the plethysmogram and corresponds to the FRC (26,27).

The unit of measurement commonly used to quantify changes in impedance amplitude is arbitrary unit (AU).The average of at least 5 sequential respiratory cycles for each patient, in each flow range, will be considered for evaluation, considering the moment of greatest stability within the final minute of the flow rate to be evaluated. Calculations to obtain delta Z were performed by subtracting the final moment of inspiration from the final moment of expiration. The changes in EELZ (∆EELZ) will be compared to the average EELZ at a flow rate of 0.5 L-kg-1-min-1 (reference flow rate). Therefore, by definition, the average ∆EELZ at the 0.5 L-kg-1-min-1 flow rate will be equal to zero. To obtain clinically meaningful values instead of AU values, the ∆EELZ will be normalized by the corresponding Delta Z at the reference flow rate (28). With this transformation, ∆EELZ can be interpreted as changes in lung aeration measured in multiples of Delta Z (tidal volumes). For example, if an infant has a mean Delta Z of 15 AU at flow rate of 0.5 L-kg-1-min-1, a ∆EELZ of 30 AU at flow rate of 2.0 L-kg-1-min-1 will be shown as 2 (an increase in lung volume twice the Delta Z at the reference flow rate).

Evaluation by ultrasound Serial measurements of thickness and thickening fraction of the diaphragm and abdominal muscle (rectus and oblique) will be collected through ultrasound images by previously trained staff. The images will be taken in the SonoSite M-Turbo® device, using an L25x (13-6 MHz) linear transducer. Heated water-based gel will be used for image acquisition.

For the diaphragm thickness measurements, the investigators used right hemidiaphragm with the linear transducer located between the anterior and middle axillary lines around the ninth intercostal space, in the diaphragmatic apposition zone (29,30). For the rectus abdominis thickness measurements the investigators used the linear transducer positioned 2 cm to the right and 2 cm above the umbilical scar. The external oblique, internal oblique and transverse muscles of the abdomen can be identified as three parallel layers, usually best visualized on the anterior axillary line, midway between the lower edge of the rib cage and the iliac crest (15,16) The window will be obtained in B-moded, and the measurement performed in M-mode. For the measurement of the thickening fraction, the investigators will use the formula ((Eins - Eex) /Ex) x 100), where Eins = thickness obtained at the end of inspiration and Eex = thickness obtained at the end of expiration.

Conditions
Bronchiolitis
Being tested
Flow rate evaluation
Keywords
Pulmonary;, Ventilation;
Medical subject headings
Bronchiolitis, Respiratory Aspiration

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Flow rate evaluationDevice

    Four different randomized flow rates will be used for evaluation: 2.0 liter.Kg-1.min-1, 1.5 liter.Kg-1.min-1, 1.0 liter.Kg-1.min-1, 0.5 liter.Kg-1.min-1. At the end of the randomized order evaluation the infant will remain in the flow of 0.5 liter.Kg-1.min-1 for 5 minutes and then return to the flow of 2.0 liter.Kg-1.min-1. The EIT parameters, ultrasound assessment, and clinical variables will be collected at the end of the 5-minute stay in each lane.

Study groups in NCT06376487
Study groupRoleWhat they receive
flow rate sequenceExperimentalFour different randomized flow rates will be used for evaluation: 2.0 liter.Kg-1.min-1, 1.5 liter.Kg-1.min-1, 1.0 liter.Kg-1.min-1, 0.5 liter.Kg-1.min-1. At the end of the randomized order evaluation the infant will remain in the flow of 0.5 liter.Kg-1.min-1 for 5 minutes and then return to the flow of 2.0 liter.Kg-1.min-1. The EIT parameters, ultrasound assessment, and clinical variables will be collected at the end of the 5-minute stay in each lane.
Receives: Device: Flow rate evaluation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. diaphragm thickening fraction

    to evaluate the diaphragm thickening fraction through ultrasound in infants with bronchiolitis using HFNC at 4 different flow rates, whether the diaphragm thickening fraction changes when the flow rate is changed

    Measured: during procedure

  2. abdominal muscle thickening fraction

    to evaluate the abdominal muscle thickening fraction through ultrasound in infants with bronchiolitis using HFNC at 4 different flow rates, whether the abdominal muscle thickening fraction changes when the flow rate is changed

    Measured: during procedure

  3. EELZ (end-expiration lung impedance)

    to evaluate the EELZ through electrical impedance tomography in infants with bronchiolitis using HFNC at 4 different flow rates, whether there is a change in the EELZ when the flow rate is changed

    Measured: during procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Apr 2024
  2. Study start1 May 2024 (estimated)
  3. Primary completion31 Jul 2025 (estimated)
  4. Study completion31 Jan 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Model description
A prospective clinical study to evaluated four different flow rate in infants with bronchiolitis using high flow nasal cannula
Masking
None (open label)
Enrolment
82 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06376487
Sponsor's protocol ID
75202423.2.0000.0071
Status last verified
Feb 2024
First submitted
16 Feb 2024
Last updated
19 Apr 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: This study will be in partnership with Childrens Hospital Los Angeles. The anonymized database will be shared containing all variables described in the methodology

Questions about this trial

What is this clinical trial studying?

A study testing Flow rate evaluation in people with Bronchiolitis, run by Hospital Israelita Albert Einstein at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Milena S Nascimento (55 11 984520061, milena.nascimento@einstein.br), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

diaphragm thickening fraction (time frame: during procedure). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in